|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000039652 |
|
最近更新日期: Date of Last Refreshed on: |
2021-02-08 10:48:53 |
|
注册时间: Date of Registration: |
2020-11-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
不可压迫性躯干出血院前控制装置及策略研究 |
|
Public title: |
Study on prehospital control device and treatment strategy of noncompressible torso hemorrhage |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不可压迫性躯干出血院前控制装置及策略研究 |
|
Scientific title: |
Study on prehospital control device and treatment strategy of noncompressible torso hemorrhage |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张画羽 |
研究负责人: |
张连阳 |
|
Applicant: |
Huayu Zhang |
Study leader: |
Lianyang Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 13509490833 |
研究负责人电话:
Study leader's |
+86 13508308400 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhanghuayu1024@163.com |
研究负责人电子邮件: Study leader's E-mail: |
dpzhangly@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国重庆渝中区长江支路10号 |
研究负责人通讯地址: |
中国重庆渝中区长江支路10号 |
|
Applicant address: |
10 Changjiang Branch Road, Yuzhong District, Chongqing, China |
Study leader's address: |
10 Changjiang Branch Road, Yuzhong District, Chongqing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
陆军特色医学中心(大坪医院) |
||
|
Applicant's institution: |
Army Characteristic Medical Center (Daping Hospital) |
||
|
研究负责人所在单位: |
陆军特色医学中心(大坪医院) |
||
|
Affiliation of the Leader: |
Army Characteristic Medical Center (Daping Hospital) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019092 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
陆军特色医学中心伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Army Medical Center of PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-10-16 00:00:00 | ||
|
伦理委员会联系人: |
王晶晶 |
||
|
Contact Name of the ethic committee: |
Jingjing Wang |
||
|
伦理委员会联系地址: |
中国重庆渝中区长江支路10号 |
||
|
Contact Address of the ethic committee: |
10 Changjiang Branch Road, Yuzhong District, Chongqing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
大坪医院创伤外科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Traumatology, Daping Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国重庆渝中区长江支路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
10 Changjiang Branch Road, Yuzhong District, Chongqing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
陆军军医大学临床技术创新培育项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
High-tech cultivation project of Army medical university |
||||||||||||||||||||||
|
研究疾病: |
不可压迫性躯干出血 |
||||||||||||||||||||||
|
Target disease: |
Noncompressible torso hemorrhage |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
1. 设计、研发、制作新型不可压迫性躯干出血控制装置; 2. 通过CT影像学数据明确腹盆部血管与体表标志的位置关系; 3. 通过健康志愿者和医务工作者评估新型不可压迫性躯干出血控制装置与现有躯干及交界部位止血装置之间的差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Design, develop and manufacture a new type of incompressible trunk bleeding control device; 2. The relationship between abdominal and pelvic vessels and body surface markers was determined by CT imaging data; 3. To evaluate the difference between the new incompressible trunk bleeding control device and the existing trunk and junction hemostatic device through healthy volunteers and medical workers. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄≥18岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Subjects aged over 18 years; |
||||||||||||||||||||||
|
排除标准: |
有腹部手术史或近6个月出现任何疾病及其它部位手术史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Subjects who had a history of abdominal surgery or had any disease or other parts of surgery in the past 6 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-12-04 00:00:00至 To 2021-12-04 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-12-04 00:00:00 至 To 2021-12-04 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无需随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization is unnecessary |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2022.09,通过咨询电子邮箱获得数据(zhanghuayu1024@163.com) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2022.09,Obtain data by consulting E-mail (zhanghuayu1024@163.com) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
制作电子版CRF,而后将数据录入Excel表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Produce electronic CRF and enter the data into Excel |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |